在加入吉利德之前，Dietmar Berger博士在赛诺菲担任CMO兼全球开发负责人，负责领导赛诺菲重点治疗领域的药物开发科学、战略和运营。在加入赛诺菲之前，Dietmar Berger博士曾在Atara、基因泰克、拜耳和安进等多家公司任职。Before joining Gilead (GILD.US), Dr. Dietmar Berger served as CMO and Global Development Head at Sanofi (SNY.US).
According to Zhito Finance APP, Gilead (GILD.US) recently announced that Dr. Dietmar Berger will join the company on January 2, 2025, succeeding Dr. Merdad Parsey as Chief Medical Officer (CMO) and will become a member of Gilead's senior leadership team.
The incoming Dr. Dietmar Berger is a board-certified internist, hematologist, and oncologist with over 25 years of extensive experience in developing and delivering Innovative Drugs across multiple therapeutic areas. He will be responsible for Gilead's leading virology, oncology, and inflammation pipeline products and will oversee Gilead's Global Development and Medical Affairs departments.
Before joining Gilead, Dr. Dietmar Berger served as CMO and Global Development Head at Sanofi, where he led drug development science, Global Strategy, and Operation in Sanofi's key therapeutic areas. Prior to joining Sanofi, Dr. Dietmar Berger held positions at several companies including Atara, Genentech, Bayer, and Amgen.
